SANTA CLARA, Calif., January 7, 2014 – Affymetrix, Inc. (NASDAQ: AFFX) will host a workshop titled, “Transforming genomic selection in complex plant and animal genomes” at PAG XXII on Monday, January 13 in San Diego. The workshop will feature key Affymetrix scientists as well as Dr. Klaus Wimmers, Professor of Genome Biology at the Leibinz Institute for Farm Animal Biology (Germany); Dr. Gary Barker of the University of Bristol (UK); and Dr. Alan L. Archibald of the Roslin Institute and the University of Edinburgh (UK). Topics will include gene expression and genotyping updates, analysis of porcine mRNAs and microRNAs, a SNP array for wheat, and high-density genotyping of Atlantic salmon.
The workshop will take place from 12:55 to 3:00 p.m. in Pacific Salon 3 at the Town and Country Resort and Convention Center.
Affymetrix technologies enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, facilitating the rapid translation of benchtop research into clinical and routine use for human health and wellness.
The company provides leadership and support, partnering with customers in pharmaceutical, diagnostic, and biotechnology companies, as well as leading academic, government, and nonprofit research institutes in their quest to use biology for a better world.
More than 2,300 microarray systems have been shipped around the world and more than 48,000 peer-reviewed papers have been published citing Affymetrix technologies. Affymetrix is headquartered in Santa Clara, California, and has manufacturing facilities in Cleveland, Ohio, San Diego, Vienna, and Singapore. The Company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe, Asia, and Latin America. For more information about Affymetrix, please visit www.affymetrix.com.
All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2012, and other SEC reports for subsequent quarterly periods.